A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

• Status: Completed
• Trial end date: 2008-10-01

Summary

This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids. During the study, patients had their corticosteroid dose gradually reduced if they responded to treatment. The anticipated time on study treatment was 12 months, and the target sample size was <100 individuals.

• Phase: Phase 3

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborator: Aspreva Pharmaceuticals
• Treatments: Mycophenolate mofetil; Mycophenolic Acid